AU2012260682B2 - Recombinant yeast expressing human H- ferritin - Google Patents

Recombinant yeast expressing human H- ferritin Download PDF

Info

Publication number
AU2012260682B2
AU2012260682B2 AU2012260682A AU2012260682A AU2012260682B2 AU 2012260682 B2 AU2012260682 B2 AU 2012260682B2 AU 2012260682 A AU2012260682 A AU 2012260682A AU 2012260682 A AU2012260682 A AU 2012260682A AU 2012260682 B2 AU2012260682 B2 AU 2012260682B2
Authority
AU
Australia
Prior art keywords
ferritin
iron
yeast
disorder
recombinant yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012260682A
Other languages
English (en)
Other versions
AU2012260682A1 (en
Inventor
James R. Connor
Ralph Lauren Keil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHYNA LLC
Original Assignee
CHYNA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHYNA LLC filed Critical CHYNA LLC
Publication of AU2012260682A1 publication Critical patent/AU2012260682A1/en
Application granted granted Critical
Publication of AU2012260682B2 publication Critical patent/AU2012260682B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012260682A 2011-05-24 2012-05-24 Recombinant yeast expressing human H- ferritin Active AU2012260682B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/114,429 US8778878B2 (en) 2007-01-29 2011-05-24 Use of ferritin to treat iron disorders
US13/114,429 2011-05-24
PCT/GB2012/000461 WO2012160333A2 (en) 2011-05-24 2012-05-24 Recombinant yeast

Publications (2)

Publication Number Publication Date
AU2012260682A1 AU2012260682A1 (en) 2013-05-02
AU2012260682B2 true AU2012260682B2 (en) 2015-07-30

Family

ID=46317426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012260682A Active AU2012260682B2 (en) 2011-05-24 2012-05-24 Recombinant yeast expressing human H- ferritin

Country Status (12)

Country Link
US (1) US8778878B2 (https=)
EP (1) EP2714888B1 (https=)
JP (1) JP2014516535A (https=)
CN (1) CN103635570A (https=)
AU (1) AU2012260682B2 (https=)
BR (1) BR112013029769B1 (https=)
CA (1) CA2874042C (https=)
DK (1) DK2714888T3 (https=)
ES (1) ES2659185T3 (https=)
NO (1) NO2714888T3 (https=)
PL (1) PL2714888T3 (https=)
WO (1) WO2012160333A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
EP1973549B1 (en) 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders
US20170273906A1 (en) * 2014-08-21 2017-09-28 Ramot At Tel-Aviv University Ltd. Targeted liposomes encapsulating iron complexes and their uses
KR101811050B1 (ko) * 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
CN108503704A (zh) 2017-02-27 2018-09-07 昆山新蕴达生物科技有限公司 穿越血脑屏障的纳米药物载体
AU2019282169A1 (en) 2018-06-04 2021-01-21 Sidero Bioscience, Llc Compositions and methods for improvement of iron metabolism and gut microbiome health
EP3976636B1 (en) * 2019-05-28 2025-05-21 PreviPharma Consulting GmbH Method for preparing iron-depleted ferritin and use thereof
CN110759986B (zh) * 2019-10-18 2023-01-31 大连工业大学 一种可逆自组装蛋白的高效制备方法
CA3220586A1 (en) * 2021-05-19 2022-11-24 Sidero Bioscience, Llc Ferritin composition tolerability
KR102691733B1 (ko) * 2021-10-13 2024-08-05 전북대학교산학협력단 효모 유래 액포를 유효성분으로 포함하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142360A1 (en) * 2007-01-29 2009-06-04 Chyna Llc Use of ferritin to treat iron deficiency disorders
WO2009120168A1 (en) * 2008-03-28 2009-10-01 Chyna Llc Use of ferritin to treat iron deficiency disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100419530B1 (ko) * 2000-11-15 2004-02-19 주식회사 알엔에이 재조합 메탄올 자화 효모를 이용한 인간 페리틴의 대량생산 방법
KR100545981B1 (ko) * 2003-04-08 2006-01-25 전북대학교산학협력단 이종중합형 패리틴 생산방법
FR2898132B1 (fr) * 2006-03-01 2012-09-28 Mane Fils V Systeme d'expression d'un gene d'interet chez la levure
US8778878B2 (en) * 2007-01-29 2014-07-15 Chyna, LLC Use of ferritin to treat iron disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142360A1 (en) * 2007-01-29 2009-06-04 Chyna Llc Use of ferritin to treat iron deficiency disorders
WO2009120168A1 (en) * 2008-03-28 2009-10-01 Chyna Llc Use of ferritin to treat iron deficiency disorders

Also Published As

Publication number Publication date
US8778878B2 (en) 2014-07-15
CA2874042A1 (en) 2012-11-29
EP2714888B1 (en) 2017-10-25
CN103635570A (zh) 2014-03-12
US20110287033A1 (en) 2011-11-24
WO2012160333A3 (en) 2013-03-07
EP2714888A2 (en) 2014-04-09
NO2714888T3 (https=) 2018-03-24
BR112013029769A2 (pt) 2017-06-06
BR112013029769B1 (pt) 2021-09-28
PL2714888T3 (pl) 2018-06-29
AU2012260682A1 (en) 2013-05-02
ES2659185T3 (es) 2018-03-14
WO2012160333A2 (en) 2012-11-29
CA2874042C (en) 2020-10-06
JP2014516535A (ja) 2014-07-17
DK2714888T3 (da) 2018-01-29

Similar Documents

Publication Publication Date Title
AU2012260682B2 (en) Recombinant yeast expressing human H- ferritin
US8071542B2 (en) Use of ferritin to treat iron deficiency disorders
CA2719577C (en) Use of ferritin to treat iron deficiency disorders
JP2022105010A (ja) 組換え酸性α－グルコシダーゼを含む製剤
KR102787774B1 (ko) 재조합 인간 산 알파-글루코시다제
KR20150121715A (ko) Ｃｓｆ１ 치료제
HU228900B1 (en) Treatment of acute lung injury and fibrosis with antagonists of alphavbetha6
US10259852B2 (en) Conjugate comprising P21 protein for the treatment of cancer
US20140322162A1 (en) Use of Ferritin to Treat Iron Disorders
AU2013335678B9 (en) Therapeutic agent for amyotrophic lateral sclerosis
US20230212233A1 (en) Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof
JP2014132029A (ja) 鉄欠乏性障害を治療するためのフェリチンの使用
US20220001020A1 (en) Combination Therapy Method of Treating Myeloproliferative Neoplasms with a Diphtheria Toxin-Human Interleukin-3 Conjugate in Combination with Other Agents
CN109475607B (zh) 包含重组酸性α-葡糖苷酶的配制品
US20240238386A1 (en) Methods for increasing red blood cell half-life and associated treatment of anemia
Fisher et al. PA, USA
BR112024002590B1 (pt) Mutante da proteína imunomoduladora recombinante de ganoderma lucidum, composição farmacêutica e dispositivo para distribuição de fármaco comprendendo a proteína recombinante e uso da mesma na prevenção, alívio ou tratamento de tumor
HK40076131A (en) Formulations comprising recombinant acid alpha-glucosidase
EA043224B1 (ru) Составы, содержащие рекомбинантную кислую альфа-глюкозидазу
MORISSETTE et al. McGill Centre for Studies in Aging
EA045409B1 (ru) Рекомбинантная человеческая кислая альфа-глюкозидаза

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)